MEDIAN Technologies to present results of a study at the Annual Meeting of the AACR in New Orleans

13 April 2016, Sophia Antipolis, France

MEDIAN Technologies to present results of a study at the Annual Meeting of the AACR in New Orleans

MEDIAN Technologies will present results of a study dealing with the monitoring of hepatocellular carcinoma in computed tomography images.

From April 17th to 20th, MEDIAN Technologies’ team will be available at Booth #855 to present the MEDIAN difference for Imaging in Oncology Trials.

MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announced today its participation in the annual meeting of the American Association for Cancer Research (AACR), to be held April 16-20, in New Orleans.

During the annual meeting of the association, one of the most important cancer research conferences worldwide and a must-attend event for cancer researchers and the broader cancer community, MEDIAN’s scientists will present results of a study dealing with the monitoring of hepatocellular carcinoma (HCC) lesions in computed tomography (CT) images. Hepatocellular carcinoma (HCC) is the most common primary liver cancer. In clinical trials, computed tomography (CT) is a widely used imaging technique for the monitoring of HCC patients, and modified RECIST (mRECIST) has been suggested as an efficient criteria because it is able to distinguish the viable part of the tumor from the necrotic part of the tumor. The study investigates the causes of inter-reader variability in evaluating the therapeutic response of HCC when relying on mRECIST. It was found that for non-mRECIST experts, variability in agreement for a partial response comes from the complexity in detecting an eventual viable part of the tumor.

On the other hand, the variability in agreement for a progressive disease comes from the complex pattern of tumor boundaries. The study concludes that mRECIST must be handled by experienced experts. A second or consensual reading is also recommended. A Computer Aided Detection system would be of great help in the detection of the viable part of tumors as well.

The study“Modified RECIST for monitoring hepatocellular carcinoma with computed tomography: Inter-reader variability of the response” will be presented during the “Imaging and Therapeutics of Metastasis” session to be held on Tuesday, Apr 19, 2016, 1:00 PM – 5:00 PM CDT. The scientific abstract of the study is available here
MEDIAN’s team will be present at Booth #855 during the whole exhibit duration (April 17-20).

More about the AACR Annual Meeting here.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66